Navigation Links
Waters Corporation Announces U.S. Drug Enforcement Administration Acquires Waters ACQUITY UPLC System to Train Forensic Chemists in Drug Screening and Profiling
Date:4/29/2009

MILFORD, Mass., April 29 /PRNewswire-FirstCall/ -- Waters Corporation (NYSE: WAT) announced today that the United States Drug Enforcement Administration (U.S. DEA) purchased a Waters(R) ACQUITY(R) UltraPerformance Liquid Chromatograph for the purpose of training new forensic chemists at the Special Testing and Research Laboratory in Dulles, Va.

Forensic laboratories are an important resource in assisting local, state and federal law enforcement agencies in monitoring and combating illicit drug abuse and trafficking, including the diversion of legally-manufactured pharmaceuticals into illegal markets. For example, data collected by the DEA from forensic laboratories about the regional use of prescription pain medicines like oxycodone and hydrocodone for non-medical purposes informs drug policy and drug enforcement initiatives and helps solve crimes. Each year, several million seized drug items are analyzed by the nation's network of government and private forensic laboratories.

Since 2004, the DEA has applied Waters ACQUITY UltraPerformance LC(R) (UPLC(R)) technology for drug profiling and has investigated this technology for drug screening analyses.

For drug profiling applications, where experts analyze trace impurities such as precursor chemicals in synthetic drugs or the constituents of natural products such as those derived from opium, a combination of UPLC and mass spectrometry (UPLC/MS/MS) has been shown to offer 2X better resolving power than HPLC and greater specificity and sensitivity than HPLC paired with photodiode array detection. These trace impurities can be important in matching a seized drug to a particular individual and potentially linking it to other cases where a similar impurity profile has been generated.

The DEA's most recent acquisition of an ACQUITY UPLC System complements its growing number of Waters ACQUITY UPLC and UPLC/MS/MS analytical systems deployed at DEA laboratories around the country.

For more information on Waters products for UPLC, visit www.waters.com/uplc.

About Waters Corporation (www.waters.com)

For 50 years, Waters Corporation (NYSE: WAT) creates business advantages for laboratory-dependent organizations by delivering practical and sustainable innovation to enable significant advancements in such areas as healthcare delivery, environmental management, food safety, and water quality worldwide.

Pioneering a connected portfolio of separations science, laboratory information management, mass spectrometry and thermal analysis, Waters technology breakthroughs and laboratory solutions provide an enduring platform for customer success.

With revenue of $1.58 billion in 2008 and 5,000 employees, Waters is driving scientific discovery and operational excellence for customers worldwide.

Waters, ACQUITY, UPLC, UltraPerformance LC, and ACQUITY UPLC are trademarks of Waters Corporation.


'/>"/>
SOURCE Waters Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. elephantjournal.com: Is Fluoridating Waters Giving Kids Cavities?
2. Video: Waters Highlights Impact of ACQUITY UPLC with Peer-to-Peer Scientist Testimonials
3. InVitria Headlines Sponsorship of WilBio's Waterside Conference
4. Waters Corporation Announces the Purchase of UPLC/MS Systems by the National Cancer Institute for Advanced Metabolomics Research
5. Red Cross Readies Shelters As Flood Waters Threaten to Top Levees
6. American Lung Association of Upper Midwest Offers Tips on Dealing With Floodwaters
7. AWWA partners with WaterSmart Innovations conference
8. Waters and LabVantage Partnership Targets Laboratory Informatics Integration to Maximize Data Management and Quality of Work
9. Next Generation Waters Successfully Reaches Over 300 Stores!
10. Leading Spring Water Brands From Nestle Waters Team Up With the American Heart Association START! Initiative
11. Waters To Unveil Xevo TQ MS Applications for Improved Drug Discovery at AAPS 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... ... February 20, 2017 , ... Today, Illuma ... plan partners, announced during the 2017 Annual HIMSS Conference & Exhibition ... for diabetic patients and integrating eye care into mainstream healthcare delivery is powered ...
(Date:2/19/2017)... ... February 19, 2017 , ... The Citadel’s new Swain Department ... being led by Amelia Joseph, Ph.D. Joseph was engaged by the college as a ... department in early 2016. After a nation-wide search, she was selected to head the ...
(Date:2/19/2017)... ... February 19, 2017 , ... ProBrand Glitch is a set of 30 glitch distortion logo reveals ... easily reveal any logo with a glitch reveal in just a few clicks of a ... and animation of each preset. Use these presets to add a uniquely animated logo to ...
(Date:2/19/2017)... ... February 19, 2017 , ... Orbita, ... join forces with Healthwise ® at HIMSS 2017 to showcase ... in evidence-based health education, technology and services, will demonstrate a voice-powered knowedge assistant ...
(Date:2/18/2017)... ... February 17, 2017 , ... Focused start-ups, not traditional health ... according to the recent NEJM Catalyst Insights Report on the New Marketplace. ... Insights Council, a qualified group of U.S. executives, clinical leaders, and clinicians at ...
Breaking Medicine News(10 mins):
(Date:2/20/2017)... 20, 2017  Today from HIMSS17, Ambra Health ... suite, announced the launch of  Ambra for Developers ... Built around modern, RESTful web-services, this is the first ... With these new APIs, IT departments at health ... data into other applications such as population health or ...
(Date:2/20/2017)... Research and Markets has announced the addition ... and Trends - Product (RFID refrigerators and RFID freezers), Application (Diagnostic ... to their offering. ... The Global RFID Blood Refrigerator and Freezer Market is poised ... 2025. This industry report analyzes the global markets ...
(Date:2/20/2017)... PUNE, India , February 20, 2017 According ... Formulation (Type (Solution, Suspension, Dry powder), Device Type (Metered dose, Dry Powder, ... to 2021" published by MarketsandMarkets, The market is projected to reach USD ... CAGR of 6.5% during the forecast period. ... ...
Breaking Medicine Technology: